When Elan (NYSE:ELN) announced back in February that it was selling its interests in Tysabri to Biogen Idec (Nasdaq:BIIB) my biggest concern was that Elan management would waste the proceeds. Elan management had made a series of questionable (if not bizarre) decisions prior to the Tysabri announcement, and I had minimal confidence that they would do the right thing – which, in my opinion, was simply to sell off the remaining assets and write a check to shareholders. Since then, the company's two major strategic decisions only reinforce my worries that Elan shareholders are not going to be well-served by management in the deployment of this cash.
Please read the full article here:
http://www.investopedia.com/stock-analysis/052113/elan-continues-make-baffling-strategic-decision-eln-thrx-gsk-prta-sny.aspx
Investopedia: Elan Continues To Make Baffling Strategic Decisions
0 comments:
Post a Comment
Click to see the code!
To insert emoticon you must added at least one space before the code.